At the forefront of therapies for rare and orphan diseasesTM
HOME CONTACT US         
Share
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
 
About Us
 



The Dr. Sol J. Barer Award for
Vision, Innovation and Leadership
Loading the player ...


RareVoice Lifetime Achievement Award – Rare Disease Congressional Caucus Briefing
Home >> About Us >> Leadership >> Senior Management Team

Senior Management Team

Senior Management Team Board of Directors Scientific Advisory Board

John F. Crowley
Chairman & Chief Executive Officer

William D. "Chip" Baird, III
Chief Financial Officer

Jay A. Barth M.D.
Chief Medical Officer

Bradley L. Campbell
Chief Operating Officer

Jeffrey P. Castelli Ph.D.
Vice President, Program Management and Portfolio Planning

Enrique Diloné Ph.D., RAC
Vice President, Technical Operations

Hung Do Ph.D.
Senior Vice President, Discovery Biology

Dipal Doshi
Senior Vice President, Business Planning and Development

Jayne C. Gershkowitz
Vice President, Patient and Professional Advocacy and Public Policy

John R. Kirk Sc.D.
Vice President, Regulatory Affairs and Quality Assurance

Kenneth W. Peist Esq.
Vice President, Legal and Intellectual Property

Daphne Quimi CPA
Vice President, Finance and Corporate Controller

Ken Valenzano Ph.D.
Senior Vice President, Preclinical Research

Julie Yu Ph.D., PMP
Vice President, Clinical Operations and Data Management


John F. Crowley
Chairman & Chief Executive Officer

John F. Crowley is the Chairman and CEO of Amicus Therapeutics, Inc.  John's involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease-a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children's lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.

John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, "The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children." The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey.  John is the author of a personal memoir:  Chasing Miracles: The Crowley Family Journey of Strength, Hope and Joy.

John is also a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard.  The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame.  He is also a member of the University Council on Science & Technology at Notre Dame.  He serves on the Executive Committee of the National Board of Directors of the Make A Wish Foundation of America and is a founding Board member of the Global Genes Project.  He also serves on the Board of Directors of Scioderm, Inc. John is a Henry Crown Fellow at the Aspen Institute.



Copyright © 2014 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy